| Inclusion Criteria: | Histologically confirmed, locally confined adenocarcinoma of the prostate.
Clinical stages T1c-T2b (AJCC 6th Edition, see Appendix III).
Zubrod Performance Scale 0-1.
Patients must be equal to or older than 18 years of age.
Combined Gleason score 7 if PSA less than 10, combined Gleason score less than 7 if PSA is 10-20.
PSA must be equal to or less than 20 ng/mL, before hormone therapy, if given (if Gleason score is 2-6, then PSA must be equal to or greater than 10 ng/mL).
Prostate volume by TRUS equal to or less than 60 cc.
No prior chemotherapy or pelvic radiation- no prior TURP, cryosurgery, TUNA, TUMT or radical surgery for carcinoma of the prostate.
No distant metastases, no clinically or pathologically involved lymph nodes.
No significant obstructive symptoms- AUA score must be equal to or less than 15 (alpha blockers allowed).
No hip prosthesis.
No major medical or psychiatric illness.
Signed study-specific informed consent form prior to study entry.
Neoadjuvant hormonal therapy beginning 2-6 months prior to registration is acceptable. The use of 5-alpha reductase inhibitors (for example, finasteride) is allowed prior to registration but should be discontinued before registration.
No previous or concurrent cancer other than basal cell or squamous cell skin cancer or in situ at another site, unless disease free for at least 5 ye
If has used a 5-alpha reductase inhibitor, it has been discontinued. |